SCHEMBL19208077

SCHEMBL19208077

CCOC(=O)c1cn(CC(=O)OC(C)(C)C)nc1N

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 5/20 0.39
ENPP2 Q13822 1/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
CHEK2 O96017 1/20 0.39
HSD17B10 Q99714 3/20 0.38
CSNK1D P48730 1/20 0.38
HPGD P15428 3/20 0.38
TSHR P16473 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
GAA P10253 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3094892 0.82 KDM4E (0.43) CRHBPCRHR2ALDH1A1KDM4EENPP2
SCHEMBL31715177 0.82 ALDH1A1 (0.43) ADORA3ADORA2AADORA1ALDH1A1KDM4E
SCHEMBL31352252 0.81 ADORA3 (0.57) ADORA3ADORA2AADORA1ALDH1A1KDM4E
SCHEMBL19236702 0.81 HSD17B10 (0.46) ALDH1A1KDM4EKMT2AMEN1HSD17B10
SCHEMBL31105945 0.81 KDM4E (0.36) ADORA3ADORA2AADORA1ALDH1A1KDM4E
SCHEMBL175330 0.81 ALDH1A1 (0.46) ADORA3ADORA2AADORA1ALDH1A1KDM4E
SCHEMBL19208570 0.80 LMNA (0.48) ALDH1A1KDM4EKMT2AHSD17B10HPGD
SCHEMBL31518572 0.80 ADORA3 (0.43) ADORA3ADORA2AADORA1CRHBPCRHR2
SCHEMBL25924621 0.80 KDM4E (0.36) ADORA3ADORA2AADORA1ALDH1A1KDM4E
SCHEMBL8694142 0.79 ALDH1A1 (0.40) ADORA3ADORA2AADORA1CRHBPCRHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12485109-B2 Pyrrolo 12.3-dipyrimidine compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2025-12-02 US disclosed
EP-3925956-B1 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BIOCRYST PHARM INC (US) 2024-04-10 EP disclosed
US-20230218578-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-07-13 US disclosed
US-20230218578-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-07-13 US disclosed
US-11559515-B2 Indole compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2023-01-24 US disclosed
US-11559515-B2 Indole compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2023-01-24 US disclosed
CN-115490751-A Factor D inhibitors 拜奥克里斯特制药公司 2022-12-20 CN disclosed
CN-109121414-B Benzopyrazole compounds and analogs thereof 拜奥克里斯特制药公司 2022-07-05 CN disclosed
EP-3411411-B3 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BIOCRYST PHARM INC (US) 2022-01-26 EP disclosed
EP-3925956-A1 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BioCryst Pharmaceuticals, Inc. (US) 2021-12-22 EP disclosed
EP-3411411-B1 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS BIOCRYST PHARM INC (US) 2021-05-19 EP disclosed
US-10849883-B2 Benzopyrazole compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2020-12-01 US disclosed
US-10849883-B2 Benzopyrazole compounds and analogues thereof BIOCRYST PHARMACEUTICALS, INC. (US) 2020-12-01 US disclosed
US-20190142802-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF BIOCRYST PHARMACEUTICALS, INC. (US) 2019-05-16 US disclosed
US-20190142802-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF BIOCRYST PHARMACEUTICALS, INC. (US) 2019-05-16 US disclosed
EP-3411411-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF Biocryst Pharmaceuticals, Inc. (US) 2018-12-12 EP disclosed
WO-2017136395-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF BIOCRYST PHARMACEUTICALS, INC. (US) 2017-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12485109-B2 Pyrrolo 12.3-dipyrimidine compounds and analogues thereof C5, DPYD, C9 ADORA3 1625/4885ADORA2A 2013/4885ADORA1 1745/4885
US-20230218578-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF C9, C5, C1QBP ADORA3 1204/4885ADORA2A 2920/4885ADORA1 2242/4885
US-11559515-B2 Indole compounds and analogues thereof C5, IDO1, IDO2 ADORA3 394/4885ADORA2A 281/4885ADORA1 374/4885
US-10849883-B2 Benzopyrazole compounds and analogues thereof C9, C5, C1QBP ADORA3 1204/4885ADORA2A 2920/4885ADORA1 2242/4885
US-20190142802-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF C9, C5, C1QBP ADORA3 1204/4885ADORA2A 2920/4885ADORA1 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.